 Connection
Paul Bunn to Mass Screening
This is a "connection" page, showing publications Paul Bunn has written about Mass Screening.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.388 |
|
|
|
-
Bunn PA. Molecular biology and early diagnosis in lung cancer. Lung Cancer. 2002 Oct; 38(1):S5-8.
Score: 0.117
-
Schenk EL, Patil T, Pacheco J, Bunn PA. 2020 Innovation-Based Optimism for Lung Cancer Outcomes. Oncologist. 2021 03; 26(3):e454-e472.
Score: 0.103
-
Pekar-Zlotin M, Hirsch FR, Soussan-Gutman L, Ilouze M, Dvir A, Boyle T, Wynes M, Miller VA, Lipson D, Palmer GA, Ali SM, Dekel S, Brenner R, Bunn PA, Peled N. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. Oncologist. 2015 Mar; 20(3):316-22.
Score: 0.069
-
Hirsch FR, Bunn PA. Progress in research on screening and genetics in lung cancer. Lancet Respir Med. 2014 Jan; 2(1):19-21.
Score: 0.063
-
Hirsch FR, Bunn PA, Dmitrovsky E, Field JK, Franklin WA, Greenberg RE, Hansen HH, Henschke CI, Rigas JR, Smith RA, Toennesen P, Mulshine JL. IV international conference on prevention and early detection of lung cancer, Reykjavik, Iceland, August 9-12, 2001. Lung Cancer. 2002 Sep; 37(3):325-44.
Score: 0.029
-
Hirsch FR, Prindiville SA, Miller YE, Franklin WA, Dempsey EC, Murphy JR, Bunn PA, Kennedy TC. Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study. J Natl Cancer Inst. 2001 Sep 19; 93(18):1385-91.
Score: 0.007
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|